Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Blood Brain Barrier Phenotype Is Determined by Medulloblastoma Subtype

DOI: 10.1158/2159-8290.CD-RW2016-067 Published June 2016
  • Article
  • Info & Metrics
Loading
  • Major finding: WNT medulloblastoma is the only medulloblastoma subtype that lacks an intact BBB.

  • Mechanism: WNT medulloblastomas secrete WNT antagonists that block normal endothelial WNT signaling.

  • Impact: WNT antagonists may increase BBB permeability and enhance drug response in medulloblastomas.

Medulloblastomas (MB), which are highly malignant pediatric brain tumors, consist of four molecular subtypes: WNT, SHH, group 3 MB, and group 4 MB, the latter three of which are most likely to exhibit a poor clinical outcome. In contrast, patients with WNT MBs who are given the standard-of-care treatment exhibit a significantly high overall 5-year survival rate. To identify the factors driving MB subtype–specific treatment response, Phoenix and colleagues examined two patient cohorts and transgenic murine models of WNT MB, SHH MB, and group 3 MB. Analysis of these patient cohorts and mouse models revealed that WNT MBs were more hemorrhagic and exhibited significantly higher vascular density and aberrant vascular endothelium than the other MB subtypes. Consistent with these findings, WNT MB endothelium exhibited downregulation of genes associated with central nervous system endothelium and the blood–brain barrier (BBB) as well as with NOTCH signaling, and WNT MBs were found to lack a functional BBB in vivo. Mechanistically, the secretion of WNT antagonists, such as dickkopf WNT pathway signaling inhibitor 1 (DKK1) and WNT inhibitor factor 1 (WIF1), by WNT MBs blocked WNT signaling in adjacent normal endothelium. Expression of the WNT7A ligand in WNT MB restored canonical WNT signaling in tumor endothelium and a functional BBB in vivo, and expression of WIF1-DKK1 in SHH MB suppressed WNT signaling and increased vessel porosity. Vincristine treatment was efficacious against control WNT MB and ineffective against WNT7A-secreting WNT MB in vivo. Together, these results identify the molecular mechanism underlying the responsiveness of WNT MB to therapy and suggest a potential therapeutic strategy to increase drug penetrance of the BBB.

Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, et al. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell 2016 Mar 31 [Epub ahead of print].

  • ©2016 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 6 (6)
June 2016
Volume 6, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Blood Brain Barrier Phenotype Is Determined by Medulloblastoma Subtype
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Blood Brain Barrier Phenotype Is Determined by Medulloblastoma Subtype
Cancer Discov June 1 2016 (6) (6) OF16; DOI: 10.1158/2159-8290.CD-RW2016-067

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Blood Brain Barrier Phenotype Is Determined by Medulloblastoma Subtype
Cancer Discov June 1 2016 (6) (6) OF16; DOI: 10.1158/2159-8290.CD-RW2016-067
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Medulloblastoma

  • ELP1 Loss Disrupts Protein Homeostasis to Promote SHH Medulloblastoma
  • Granule Neuron Precursor–Derived Astrocytes Promote Medulloblastoma
  • Germline GPR161 Mutations Are Associated With Infant Medulloblastoma
Show more Medulloblastoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement